Clinical Trial

MB-CART2019.1 in Refractory Multiple Sclerosis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-10; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2026-05-06
Trial Details
NCT Number NCT07178431
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Multiple Sclerosis, CAR T Cell Therapy
Enrollment 26 participants
Start Date 2026-04-01
Primary Completion 2030-08-16 (estimated)
Study Completion 2030-08-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-11